Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a note issued to investors on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital dropped their price target on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 23rd.

Evogene Stock Performance

Shares of Evogene stock opened at $2.70 on Monday. Evogene has a 52-week low of $2.61 and a 52-week high of $10.40. The company has a fifty day moving average of $4.01 and a 200-day moving average of $6.03. The stock has a market capitalization of $111.28 million, a price-to-earnings ratio of -5.87 and a beta of 1.40.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The business had revenue of $0.91 million for the quarter. Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Evogene stock. BNP Paribas Financial Markets increased its position in Evogene Ltd. (NASDAQ:EVGN) by 30.8% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 91,400 shares of the biotechnology company’s stock after purchasing an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.22% of Evogene worth $69,000 as of its most recent filing with the Securities & Exchange Commission. 10.40% of the stock is owned by hedge funds and other institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.